In this work, we showed that inhibition of CTSB has the ability to reverse the harmful effects of inflammatory mediators present in SSc sera on Fli1 and ERG protein levels, suggesting that targeting cathepsin B could be an attractive strategy for SSc vascular disease. The gene discussed is CTSB; the disease is systemic sclerosis.